Antibiotic loaded inhalable liposomal nanoparticles against lower respiratory tract infections: Challenges, recent advances, and future perspectives
VK Panthi, KE Fairfull-Smith, N Islam - Journal of Drug Delivery Science …, 2024 - Elsevier
Lower respiratory tract infections (LRTIs) are inherited disorders which often causes chronic
respiratory infections for which patients repeatedly receive oral antibiotics, particularly …
respiratory infections for which patients repeatedly receive oral antibiotics, particularly …
[图书][B] Nelson's pediatric antimicrobial therapy
JS Bradley - 2012 - publications.aap.org
Welcome to the 29th edition of Nelson's Pediatric Antimicrobial Therapy, the third edition
written during the COVID-19 pandemic, which continues to significantly affect our lives and …
written during the COVID-19 pandemic, which continues to significantly affect our lives and …
Inhaled antibiotics: A promising drug delivery strategies for efficient treatment of lower respiratory tract infections (LRTIs) associated with antibiotic resistant biofilm …
N Islam, D Reid - Respiratory Medicine, 2024 - Elsevier
Antibiotic-resistant bacteria associated with LRTIs are frequently associated with inefficient
treatment outcomes. Antibiotic-resistant Streptococcus pneumoniae, Haemophilus …
treatment outcomes. Antibiotic-resistant Streptococcus pneumoniae, Haemophilus …
Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration
Many of the current pandemic threats are caused by viruses that infect the respiratory tract.
Remarkably though, the majority of vaccines and antiviral drugs are administered via …
Remarkably though, the majority of vaccines and antiviral drugs are administered via …
Structure–Interaction Relationship of Polymyxins with Lung Surfactant
Multidrug-resistant Gram-negative bacteria present an urgent and formidable threat to the
global public health. Polymyxins have emerged as a last-resort therapy against these …
global public health. Polymyxins have emerged as a last-resort therapy against these …
[HTML][HTML] Traits, trends and hits of orphan drug designations in cystic fibrosis
E Costa, S Girotti, HA van den Ham, M Cipolli… - Journal of Cystic …, 2023 - Elsevier
Abstract Background In the United States (US) and in Europe, cystic fibrosis (CF) qualifies as
a rare disease, thus positioning the field to benefit from regulatory incentives provided by …
a rare disease, thus positioning the field to benefit from regulatory incentives provided by …
[HTML][HTML] Optimizing in vitro phage-ciprofloxacin combination formulation for respiratory therapy of multi-drug resistant Pseudomonas aeruginosa infections
Q Hong, RYK Chang, O Assafiri, S Morales… - International Journal of …, 2024 - Elsevier
Respiratory infection caused by multi-drug resistant (MDR) Pseudomonas aeruginosa is
challenging to treat. In this study, we investigate the optimal dose of anti-pseudomonas …
challenging to treat. In this study, we investigate the optimal dose of anti-pseudomonas …
Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy
PR Burgel, M Ballmann, P Drevinek… - BMJ open …, 2024 - bmjopenrespres.bmj.com
The major cause of mortality in people with cystic fibrosis (pwCF) is progressive lung
disease characterised by acute and chronic infections, the accumulation of mucus, airway …
disease characterised by acute and chronic infections, the accumulation of mucus, airway …
Structural Insights into the Lipopolysaccharide Transport (Lpt) System as a Novel Antibiotic Target
Y Yoon, S Song - Journal of Microbiology, 2024 - Springer
Lipopolysaccharide (LPS) is a critical component of the extracellular leaflet within the
bacterial outer membrane, forming an effective physical barrier against environmental …
bacterial outer membrane, forming an effective physical barrier against environmental …
Development of Quinazolinone Derivatives as Modulators of Virulence Factors of Pseudomonas aeruginosa Cystic Fibrosis Strains
G Carullo, G Di Bonaventura, S Rossi, V Lupetti… - Molecules, 2023 - mdpi.com
Pseudomonas aeruginosa (PA), one of the ESKAPE pathogens, is an opportunistic Gram-
negative bacterium responsible for nosocomial infections in humans but also for infections in …
negative bacterium responsible for nosocomial infections in humans but also for infections in …